Just a routine day for me in the gym to assist in the prevention of age related sarcopenia.
power clean and jerk from the hang, 90-95% BW 10-15 reps with no breaks....continual.
dips with 120lbs....2-3 sets of 5
straight leg hand stand pushups ( extremely difficult) attempt to do 5 with breaks in between.
10 minutes on treadmill at 6mph.
pullup switches ( switching position mid pull for 10-15 reps)
platform jumps with 225lbs 18-20 inches off ground. 10-15 reps with breaks every 5 reps.
heavy bag work for 5-10 minutes with breaks every 2-3 minutes. ( really intense)...i.e. not tae bo [thumb]
overhead squat 90-110% BW for 5-10 reps.
stair climb with 50-60% BW for 1 minute at level 20(highest level).
my theory is that the addressing of fast twitch muscle fibers should be of primary concern in the battle against sarcopenia(being that aging hits these fibers the hardest), and many of my movements involve the use of these fibers almost exclusively. I also try to incorporate movements that will enlarge the capacity of the left ventricle giving me a larger LVEF ( left ventricle ejection fraction) and providing more oxygen for my body.
I have recently addressed the issue of sarcopenia via a discovery in asthma medication
Br J Pharmacol. 2006 Jan 23; : 16432501
Systemic administration of beta(2)-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.
[My paper] James G Ryall , Martin N Sillence , Gordon S Lynch
beta(2)-Adrenoceptor agonists provide a potential therapy for muscle wasting and weakness, but their use may be limited by adverse effects on the heart, mediated in part, by beta(1)-adrenoceptor activation.Two beta(2)-agonists, formoterol and salmeterol, are approved for treating asthma and have an extended duration of action and increased safety, associated with greater beta(2)-adrenoceptor selectivity.The pharmacological profiles of formoterol and salmeterol and their effects on skeletal and cardiac muscle mass were investigated in 12-week-old, male F344 rats. Formoterol and salmeterol were each administered via daily i.p. injection at one of seven doses (ranging from 1 to 2000 mug kg(-1) day(-1)), for 4 weeks. Rats were anaesthetised and the EDL and soleus muscles and the heart were excised and weighed. Dose-response curves were constructed based on skeletal and cardiac muscle hypertrophy.Formoterol was more potent than salmeterol, with a significantly lower ED(50) in EDL muscles (1 and 130 mug kg(-1) day(-1), P <0.05), whereas salmeterol had greater intrinsic activity than formoterol in both EDL and soleus muscles (12% greater hypertrophy than formoterol). The drugs had similar potency and intrinsic activity in the heart, with a smaller leftward shift for formoterol than seen in skeletal muscle. A dose of 25 mug kg(-1) day(-1) of formoterol elicited greater EDL and soleus hypertrophy than salmeterol, but resulted in similar beta-adrenoceptor downregulation.These results show that doses as low as 1 mug kg(-1) day(-1) of formoterol can elicit significant muscle hypertrophy with minimal cardiac hypertrophy and provide important information regarding the potential therapeutic use of formoterol and salmeterol for muscle wasting.British Journal of Pharmacology advance online publication, 23 January 2006; doi:10.1038/sj.bjp.0706669.
while I'm monitoring my LVEF via echocardiogram, I'll be paying extra close attention to the wall thickness of my heart and adjusting the dosage or stopping altogether if the SARM increases wall thickness to much.I'll keep you guys posted as to the results. [glasses]
I'm also looking into myostatin mutators like MYO-021 (wyeth experimental muscular dystrophy drug) which have shown much promise in regards to sarcopenia interventions.(currently in phase III.